| Product Name | Tandutinib - API |
| Product Code | DA-T332-a |
| Chemical name | Tandutinib |
| Synonyms | 4-[6-Methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-1-piperazinecarboxamide; [4-[6-Methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl]piperazinyl]-N-[4-(methylethoxy)phenyl]carboxamide; 1-Piperazinecarboxamide, 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-; |
| Impurity | NA |
| CAS Number | 387867-13-2 |
| Alternate CAS # | NA |
| Molecular form | C31H42N6O4 |
| Appearance | White to Off-White Solid |
| Melting Point | NA |
| Mol. Weight | 562.72 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | impurities,metabolites,pharmaceutical standards,intermediates,Fine Chemicals |
| Boiling Point | NA |
| Applications | An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) and other cancer indications. The drug exhibited limited activity as a single agent in phase I and II clinical trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML when administered in combination with cytarabine and daunorubicin. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
